PWE-013 Selective cytotoxicity of aberrantly glycosylated MUC1 binding-PS1 photoimmunoconjugates for oesophageal adenocarcinoma targeted photodynamic therapy in primary and metastatic disease

Introduction

Targeted photodynamic therapy (PDT) has the potential to overcome current limitations of PDT agents by offering specific tumour kill with reduced side effects. We have previously shown expression of AG-MUC1, an epithelial cancer target bound by the antibody HuHMFG1, in patients with Barrett9s with dysplasia, oesophageal adenocarcinoma (OA) and on OE19, an OA cell line. We have recently developed and characterised...